Compare ATHM & VCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATHM | VCEL |
|---|---|---|
| Founded | 2008 | 1989 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2013 | 1996 |
| Metric | ATHM | VCEL |
|---|---|---|
| Price | $17.95 | $33.58 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $28.00 | ★ $58.50 |
| AVG Volume (30 Days) | 547.7K | ★ 742.6K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | ★ 9.88% | N/A |
| EPS Growth | N/A | ★ 60.00 |
| EPS | N/A | ★ 0.32 |
| Revenue | N/A | ★ $276,259,000.00 |
| Revenue This Year | N/A | $19.10 |
| Revenue Next Year | $4.82 | $17.95 |
| P/E Ratio | ★ $12.13 | $104.91 |
| Revenue Growth | N/A | ★ 16.45 |
| 52 Week Low | $16.74 | $28.95 |
| 52 Week High | $29.92 | $45.97 |
| Indicator | ATHM | VCEL |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 51.53 |
| Support Level | $17.87 | $31.24 |
| Resistance Level | $19.87 | $34.77 |
| Average True Range (ATR) | 0.49 | 1.66 |
| MACD | 0.18 | 0.39 |
| Stochastic Oscillator | 72.73 | 74.14 |
Founded in 2008 as a media content platform, Autohome is the leading online automobile platform in China, ranking first among automotive service platforms in terms of mobile daily active users, according to QuestMobile. Through its two websites, autohome.com.cn and che168.com, Autohome delivers comprehensive, independent and interactive content and tools to automobile consumers as well as a full suite of services to automakers and dealers. According to iResearch, the company was the largest online automotive advertising and lead generation service provider, in terms of media services and lead generation revenue, in China's online auto platform media advertising market.
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.